News brief
On 2026-09-24, according to Xiniu Data, Enveda Biosciences completed Series E financing, raising USD 311 million. Investors were lead investor Catalio Capital Management, Durable Capital Partners, ICONIQ, Lightspeed and others. The company is a developer of AI natural product drugs.
Connected profiles
Explore
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年9月24日，据烯牛数据报道，Enveda Biosciences完成E轮融资，金额3.11亿美元。投资方为Catalio Capital Management领投，Durable Capital Partners，ICONIQ，Lightspeed等。该公司为AI天然产物药物研发商。